Q2 FY2026 EarningsQ2 FY26 beat revenue consensus with $0.18M vs. $0.17M expected, driven by increased IGALMI® volume and deeper GPO discounts. GAAP EPS of -$0.49 beat the -$0.58 consensus due to aggressive R&D cost-cutting (-69% YoY) despite higher legal fees in SG&A. However, the company faces severe liquidity risks with a cash runway only through late August 2026 and substantial doubt about its ability to continue as a going concern, pending a critical strategic alternative deadline of August 21, 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bioxcel Therap(BTAI) the Revenue is 182 K (+51.67%);the EBIT is -10.19 M (+35.7%);the EPS is -0.486 (+80.15%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B51.67%
----
----
EBIT
-0.01B35.70%
----
----
EPS
-0.485680.15%
----
----
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf